Epstein-Barr virus-associated lymphoproliferative disease in oral cavity in a renal transplant recipient: A case report

Pediatric Transplantation

Volumn 11, Issue 3, 2007, Pages 340-344

  Johnson, J ^a   Kerecuk, L ^b   Harrison, M ^a   Taylor, J O ^b   Odell, E ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Dental; Epstein Barr virus; Gingival hyperplasia; Immunosuppression; Post transplant lymphoproliferative disease; Renal; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; PREDNISOLONE; VINCRISTINE;

ARTICLE; CASE REPORT; CLINICAL FEATURE; CONGENITAL NEPHROTIC SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; GINGIVA HYPERPLASIA; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; SCHOOL CHILD; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS TITRATION;

ANTINEOPLASTIC AGENTS; BIOPSY; CHILD; CYCLOPHOSPHAMIDE; DIAGNOSIS, DIFFERENTIAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GINGIVAL DISEASES; HUMANS; HYPERPLASIA; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; PREDNISOLONE; VINCRISTINE;

EID: 34147169950     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00694.x     Document Type: Article

References (22)

1. SRIVASTAVA T, ZWICK D, ROTHBERG P, WARADY BA. Post-transplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999: 13: 748-754.
2. PICKHARDT PJ, SIEGAL MJ, HAYASHI RJ, KELLY M. Post-transplantation lymphoproliferative disorder in children: Clinical histopathology, and imaging features. Radiology 2000: 217: 16-25.
3. CAPELLO D, ROSSI D, GAIDANO G. Post-transplant lymphoproliferative disorders: Molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 2005: 23: 61-67.
4. PAYA CV, FUNG JJ, NALESNIK MA, et al. Epstein-Barr Virus-induced posttransplant lymphoproliferative disorders. ASTA/ASTP EBV-PTLD Task Force and The Mayo Clinica Organized International Consensus Development Meeting. Transplantation 1999: 68: 1517-1525.
5. LOREN AW, PORTER DL, STADTMAUER EA, TSAI DE. Post-transplant lymphoproliferative disorder: A review. Bone Marrow Transplant 2003: 31: 145-155.
6. RANDHAWA PS, DEMETRIS AJ, PIETRZAK B, et al. Histopathology of renal posttransplant lymphoproliferative: Comparison with rejection using the Banff Schema. Am J Kidney Dis 1996: 28: 578-584.
7. PRAGHAKARAN K, WISE B, CHEN A, SCHWARZ K, COLOMBANI P. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 1999: 34: 112-115.
8. DHARNIDHARKA VR, SULLIVAN EK, STABLEIN DM, TEJANI AH, HARMON WE. Risk factors for PTLD in kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 2001: 71: 1065-1068.
9. FUNCH DP, BRADY J, KO HH, DREYER NA, WALKER AM. Methods and objectives of a large US multicentre case control study of post-transplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res 2002: 159: 81-88.
10. WILDE GE, MOORE DJ, BELLAH RD. Post-transplantation lymphoproliferative disorder in pediatric recipients of solid organ transplant: Timing and location of disease. AJR Am J Roentgenol 2005: 185: 1335-1341.
11. SWINNE LJ, MULLEN GM, CARR TJ, COSTANZO MR, FISHER RI. Aggressive treatment for post-transplant lymphoproliferation. Blood 1995: 86: 3333-3337.
12. KOPF S, TONSHOFF B. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatric Nephrol 2004: 19: 365-368.
13. SHROFF R, REES L. The post-transplant lymphoproliferative disorder - A literature review. Pediatr Nephrol 2004: 19: 369-377.
14. SHROFF R, TRUMPETER R, CUBITT D, THAKER U. Epstein-Barr virus monitoring in paediatric renal transplant recipients. Pediatr Nephrol 2002: 17: 770-775.
15. SHAPIRO NL, STROCKER AM. Adenotonsillar hypertrophy and Epstein Barr virus in pediatric organ transplant recipients. Laryngoscope 2001: 111: 997-1001.
16. KOPF S, TONSHOFF B. Adenotonsillar hypertrophy and post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatr Nephrol 2004: 19: 471-472.
17. HARRIS NL, SWERDLOW SH, FRIZZERA G, KNOWES DM. Post-transplant lymphoproliferative disorders. In: JAFFE ES, HARRIS NL, STEIN H, VARDIMAN J, eds. World Heath Organisation. Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001, pp. 264-269.
18. BALDANTI F, GROSSI P, FURIONE M, et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiology 2000: 38: 613-9.
19. STARZL TE, PORTER KA, IWATSUKI S. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1998: 1: 583-587.
20. BENKERROU M, JAIS JP, LEBLOND V. Anti-B cell monoclonal antibody treatment for severe post-transplant lymphoproliferative disorder: Prognosis factors and long-term outcome. Blood 1998: 92: 3137-3142.
21. HO M, JAFFE R, MILLER G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988: 45: 719-27.
22. MIHALOV ML, GATTUSO P, ABRAHAM K, HOLMES EW, REDDY V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single centre. Clin Transplant 1996: 10: 248-55.